We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-1.74%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$2.74B
AUM Growth
+$339M
Cap. Flow
-$310M
Cap. Flow %
-11.3%
Top 10 Hldgs %
45.15%
Holding
404
New
120
Increased
93
Reduced
80
Closed
88

Top Buys

Rank Stock Value
1
TLT icon
iShares 20+ Year Treasury Bond ETF
TLT
+$23.4M
2
XOM icon
ExxonMobil
XOM
+$15.3M
3
PXD
Pioneer Natural Resource Co.
PXD
+$12.1M
4
MRK icon
Merck
MRK
+$9.03M
5
BPMC
Blueprint Medicines
BPMC
+$8.62M

Top Sells

Rank Stock Value
1
TPST icon
Tempest Therapeutics
TPST
+$53.9M
2
AGN
Allergan plc
AGN
+$33.8M
3
IWM icon
iShares Russell 2000 ETF
IWM
+$24.7M
4
MBLY
Mobileye N.V.
MBLY
+$7.21M
5
MNKD icon
MannKind Corp
MNKD
+$5.7M

Sector Composition

Rank Sector Weight
1 Healthcare 8.27%
2 Energy 1.27%
3 Technology 0.21%
4 Communication Services 0.15%
5 Industrials 0.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CERS icon
326
Cerus
CERS
$577M
– –
-100,000
Closed -$417K
CLLS
327
Cellectis
CLLS
$289M
– –
-22,700
Closed -$785K
CRDF icon
328
Cardiff Oncology
CRDF
$63.2M
– –
-208
Closed -$102K
CTSO icon
329
PUT
Cytosorbents Corp
CTSO
$22.6M
– –
-168
Closed -$222K
CYH icon
330
Community Health Systems
CYH
$385M
– –
-33,358
Closed -$1.5M
DHR icon
331
CALL
Danaher
DHR
$138B
– –
-1,488
Closed -$8.49M
DHR icon
332
Danaher
DHR
$138B
– –
-92,920
Closed -$5.3M
DHR icon
333
PUT
Danaher
DHR
$138B
– –
-1,488
Closed -$8.49M
ESPR
334
DELISTED
Esperion Therapeutics
ESPR
– –
-5,000
Closed -$489K
HALO icon
335
Halozyme
HALO
$9.87B
– –
-191,621
Closed -$3.37M
INCY icon
336
CALL
Incyte
INCY
$25.4B
– –
-201
Closed -$1.84M
INCY icon
337
PUT
Incyte
INCY
$25.4B
– –
-478
Closed -$4.38M
IONS icon
338
PUT
Ionis Pharmaceuticals
IONS
$8.97B
– –
-65
Closed -$414K
IWM icon
339
iShares Russell 2000 ETF
IWM
$79.7B
– –
-198,690
Closed -$24.7M
MDGL icon
340
Madrigal Pharmaceuticals
MDGL
$12.5B
– –
-11,400
Closed -$794K
LITS
341
CALL
Lite Strategy Inc
LITS
$32.7M
– –
-70
Closed -$252K
NVO
342
CALL
Novo Nordisk
NVO
$229B
– –
-8,444
Closed -$22.5M
OMER icon
343
PUT
Omeros
OMER
$847M
– –
-120
Closed -$264K
PBYI icon
344
Puma Biotechnology
PBYI
$404M
– –
-9,044
Closed -$1.64M
PFE icon
345
CALL
Pfizer
PFE
$143B
– –
-19,321
Closed -$63.8M
PFE icon
346
PUT
Pfizer
PFE
$143B
– –
-2,814
Closed -$9.29M
PSTV icon
347
PUT
Plus Therapeutics
PSTV
$24.9M
– –
0
– -$31K
RDHL
348
Redhill Biopharma
RDHL
$4.26M
– –
-108
Closed -$1.57M
RMTI icon
349
CALL
Rockwell Medical
RMTI
$27.6M
– –
-18
Closed -$2.19M
SNOA icon
350
Sonoma Pharmaceuticals
SNOA
$5.31M
– –
-465
Closed -$352K
12 13
14
15 16

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
AB
Aozora Bank Tokyo, Japan $43.6M AUM 1.15% 1-Year Est. Return

Sabby Management's Q2 2015 Portfolio in Review

As of Q2 2015, Sabby Management held 404 positions worth $2.74B, up 14% from $2.4B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Sabby Management withdrew a net $310M in Q2 2015, closing 88 positions and reducing 80 holdings. Its most notable exit was Allergan plc, an estimated $33.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 8.3% of assets, down from 9.4% a quarter earlier, followed by Energy and Technology.

Against the trend, Sabby Management opened a new position in ExxonMobil worth $14.8M.

  • Sabby Management's largest Q2 2015 buy was ExxonMobil: 178,310 shares worth $14.8M.
  • Sabby Management added most to iShares 20+ Year Treasury Bond ETF in Q2 2015, an estimated $23.4M increase.
  • Sabby Management's biggest Q2 2015 reduction was Tempest Therapeutics, cutting an estimated $53.9M.
  • Sabby Management fully exited Allergan plc in Q2 2015, selling an estimated $33.8M.
  • Sabby Management's ten largest holdings make up 45% of its $2.74B portfolio in Q2 2015.
  • Sabby Management opened 120 new positions and closed 88 in Q2 2015.
  • Sabby Management's portfolio value rose 14% quarter-over-quarter to $2.74B.

Based on Sabby Management's 13F filing for Q2 2015, filed 14 Aug 2015.